Mucosal Immunology for HIV Vaccine Development
CIHR is pleased to announce funding to support three new teams composed of Canadian and international researchers who will improve our understanding of the mucosal immune response to HIV. Under the auspices of the Canadian HIV Vaccine Initiative (CHVI), the teams have been awarded grants totalling $3.4 million from the Canadian Institutes of Health Research (CIHR), in partnership with the Bill & Melinda Gates Foundation.
Mucosal immunology (the role of mucus membranes in the body’s immune response to microbes) has emerged as a critical area for investigation in the field of HIV vaccines. A better understanding of early events in HIV exposure may lead to new strategies to block infection or establish early, stringent control of HIV and prevent further spread.
The three research teams will be led by:
- Dr. Adam Burgener, University of Manitoba
- Dr. Rupert Kaul, University of Toronto
- Dr. Charu Kaushic, McMaster University
- Date modified: